Vegan Friendly Crassocephalum rabens Extract (RabenWhite®) in Anti-aging

October 18, 2024 01:00 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

TAIPEI and TAICHUNG, Oct. 18, 2024 /PRNewswire/ -- Skin is the largest organ (~15% of the total body weight) and represents overall well-being in humans, especially in aging. The global anti-aging market is around USD 64 billion in 2022, and the market size is projected to reach 121.8 billion by 20301. The high-profile products on rejuvenating aged skin are mostly associated with collagen-derived formulas. Collagen is often obtained from animal sources (e.g., fish skin), but few plant-based options distribute in market. Therefore, vegans have limited options in skin care products. The plant-based collagen market will grow to USD 12.3 billion by 20322.  Considering the rise of beauty-from-within market, effective botanical ingredients have potential to become alternative anti-aging solutions. The clinical-backed dosages of plant-based materials are 2,500-5,000 mg per day3,4. It is difficult to use these dietary ingredients to develop low-dose product applications.

The novel product Crassocephalum rabens extract, under the trade name RabenWhite®, standardized with the active compound 1,2-di-O-linolenoyl-3-O-β-galactosyl-sn-glycerol (dLGG). Crassocephalum rabens, also called Crassocephalum crepidioides, is a vegetable and herbal plant that used as folk remedy in Taiwan, Vietnam, China, India, and some African countries5. Pharmacological studies have proved that C. rabens possesses anti-inflammatory and anti-cancer activities, while Greenyn Biotechnology are the first company to demonstrate its commercial application in slowing skin aging. The index compound dLGG is a phytogalactolipid that exhibits anti-oxidative and anti-inflammatory effects on cells and rodents. A randomized, double-blind, placebo-controlled clinical study showed that 200 mg of RabenWhite® (daily dosage) could significantly improve skin wrinkles, brightness, collagen content, and UV spots in subjects in 4 weeks compared with the results of placebo group6. Especially, RabenWhite® reduced average skin wrinkles and increased collagen content levels by 29.9% and 9.8%, respectively, in 4 weeks as compared to the baseline results (Figures 1-3). Also, it could increase skin brightness value by 2.1% after the study (Figure 4).     


To produce the high quality of RabenWhite®, Greenyn Biotechnology has optimized the natural cultivation conditions of C. rabens with local farmers and leveraged a unique supercritical fluid extraction method to highly increase the content of dLGG in RabenWhite® by ten times higher than wild C. rabens. Collaboration with local farmers and using eco-friendly supercritical fluid extraction are positively correlated with the sprits of ESG with respect to social and environmental responsibilities. Moreover, the product is manufactured in the factory under the guidelines of ISO22000, FSSC 22000, HACCP, GMP, and Halal. In a word, the vegan friendly and highly safe plan extract can provide a new anti-aging option to slow our skin aging. 

Reference:

1.      https://www.precedenceresearch.com/anti-aging-market

2.      https://www.futuremarketinsights.com/reports/plant-based-collagen-market

3.      https://revivecollagen.com/products/revive-collagen-vegan-the-worlds-first-clinically-proven-vegan-collagen

4.      Lin et al., J. Funct. Foods, Vol. 112, pp. 105955, 2024.

5.      Can et al., Oxid. Med. Cell Longev., Vol. 2020, pp. 2483187, 2020.

6.      Kuan et al., Nutrients, Vol. 14, pp. 2655. 2022.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.